Extracorporeal Life Support Organization Registry International Report 2022: 100,000 Survivors
- PMID: 38181413
- PMCID: PMC10962646
- DOI: 10.1097/MAT.0000000000002128
Extracorporeal Life Support Organization Registry International Report 2022: 100,000 Survivors
Abstract
The Extracorporeal Life Support Organization (ELSO) maintains the world's largest extracorporeal membrane oxygenation (ECMO) registry by volume, center participation, and international scope. This 2022 ELSO Registry Report describes the program characteristics of ECMO centers, processes of ECMO care, and reported outcomes. Neonates (0-28 days), children (29 days-17 years), and adults (≥18 years) supported with ECMO from 2009 through 2022 and reported to the ELSO Registry were included. This report describes adjunctive therapies, support modes, treatments, complications, and survival outcomes. Data are presented descriptively as counts and percent or median and interquartile range (IQR) by year, group, or level. Missing values were excluded before calculating descriptive statistics. Complications are reported per 1,000 ECMO hours. From 2009 to 2022, 154,568 ECMO runs were entered into the ELSO Registry. Seven hundred and eighty centers submitted data during this time (557 in 2022). Since 2009, the median annual number of adult ECMO runs per center per year increased from 4 to 15, whereas for pediatric and neonatal runs, the rate decreased from 12 to 7. Over 50% of patients were transferred to the reporting ECMO center; 20% of these patients were transported with ECMO. The use of prone positioning before respiratory ECMO increased from 15% (2019) to 44% (2021) for adults during the coronavirus disease-2019 (COVID-19) pandemic. Survival to hospital discharge was greatest at 68.5% for neonatal respiratory support and lowest at 29.5% for ECPR delivered to adults. By 2022, the Registry had enrolled its 200,000th ECMO patient and 100,000th patient discharged alive. Since its inception, the ELSO Registry has helped centers measure and compare outcomes across its member centers and strategies of care. Continued growth and development of the Registry will aim to bolster its utility to patients and centers.
Copyright © ASAIO 2024.
Conflict of interest statement
Disclosure: J.E.T. is the Chair of the Registry Committee of the Extracorporeal Life Support Organization (ELSO). P.S.B. receives salary support from ELSO. G.M. is the President of ELSO. M.P. is the Immediate past President of ELSO. D.B. receives research support from and consults for LivaNova. He has been on the medical advisory boards for Abiomed, Xenios, Medtronic, Inspira, and Cellenkos. He is the President-elect of ELSO and the Chair of the Executive Committee of the International ECMO Network (ECMONet), and he writes for UpToDate. M.A., A.H., and K.R. are the Immediate Past Co-Chairs of the Scientific Oversight Committee of ELSO. P.R. is the Executive Director of ELSO. C.S. is the Chief Executive Officer (CEO) of ELSO. N.A.B. is the President of European Chapter of ELSO. N.A.B. has been on the medical advisory boards for Xenios and Baxter. T.M. is on the Board of Directors of ELSO. R.D.G. is the President of the Latin-American Chapter of ELSO. P.M.K. is the President of the South West Asia and Africa Chapter of ELSO. J.F.F. is the President of Asia-Pacific Chapter of ELSO. P.M.A.A. is Treasurer of ELSO Board of Directors. P.M.A.A. is funded by U.S. DoD PRMRP Clinical Trial Award #W81XWH2210301, NIH (R13HD104432) and FDA UCSF-Stanford Center of Excellence in Regulatory Sciences and Innovation (U01FD004979/U01FD005978). None of the funding sources were involved in the design or conduct of the study, collection, management, analysis, or interpretation of the data, or preparation, review, or approval of the manuscript. No other conflicts of interest reported. R.P.B. is a member of the Board of Directors for ELSO and receives funding from the National Heart, Lung, And Blood Institute (R01 HL153519).
Comment in
-
ELSO Registry Reports: A New Look.ASAIO J. 2024 Feb 1;70(2):144-145. doi: 10.1097/MAT.0000000000002145. Epub 2024 Jan 26. ASAIO J. 2024. PMID: 38289567 No abstract available.
Similar articles
-
Aspergillus infection and extracorporeal membrane oxygenation support.J Intensive Care Med. 2013 May-Jun;28(3):178-84. doi: 10.1177/0885066611432542. Epub 2012 Feb 11. J Intensive Care Med. 2013. PMID: 22328597
-
The changing demographics of neonatal extracorporeal membrane oxygenation patients reported to the Extracorporeal Life Support Organization (ELSO) Registry.Pediatrics. 2000 Dec;106(6):1334-8. doi: 10.1542/peds.106.6.1334. Pediatrics. 2000. PMID: 11099585
-
Cardiopulmonary resuscitation requiring extracorporeal membrane oxygenation in the elderly: a review of the Extracorporeal Life Support Organization registry.ASAIO J. 2013 May-Jun;59(3):211-5. doi: 10.1097/MAT.0b013e31828fd6e5. ASAIO J. 2013. PMID: 23644606
-
Extracorporeal membrane oxygenation support among children with adenovirus infection: a review of the Extracorporeal Life Support Organization registry.ASAIO J. 2014 Jan-Feb;60(1):49-56. doi: 10.1097/MAT.0000000000000013. ASAIO J. 2014. PMID: 24270230 Review.
-
Update on extracorporeal life support 2004.Semin Perinatol. 2005 Feb;29(1):24-33. doi: 10.1053/j.semperi.2005.02.005. Semin Perinatol. 2005. PMID: 15921149 Review.
Cited by
-
Extracorporeal membrane oxygenation in critically ill patients with active hematologic and non-hematologic malignancy: a literature review.Front Med (Lausanne). 2024 Oct 22;11:1394051. doi: 10.3389/fmed.2024.1394051. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39502645 Free PMC article. Review.
-
Acute Ischemic Stroke during Extracorporeal Membrane Oxygenation (ECMO): A Narrative Review of the Literature.J Clin Med. 2024 Oct 9;13(19):6014. doi: 10.3390/jcm13196014. J Clin Med. 2024. PMID: 39408073 Free PMC article. Review.
-
A narrative review on antimicrobial dosing in adult critically ill patients on extracorporeal membrane oxygenation.Crit Care. 2024 Oct 4;28(1):326. doi: 10.1186/s13054-024-05101-z. Crit Care. 2024. PMID: 39367501 Free PMC article. Review.
-
No Time to Die.Arq Bras Cardiol. 2024 Sep 27;121(8):e20240512. doi: 10.36660/abc.20240512. eCollection 2024. Arq Bras Cardiol. 2024. PMID: 39356948 Free PMC article. English, Portuguese. No abstract available.
-
More than one pathway: ECMO training and credentialing.Crit Care Resusc. 2024 Jul 31;26(3):217-218. doi: 10.1016/j.ccrj.2024.06.004. eCollection 2024 Sep. Crit Care Resusc. 2024. PMID: 39355505 Free PMC article. No abstract available.
References
-
- Toomasian JM, Snedecor SM, Cornell RG, Cilley RE, Bartlett RH: National experience with extracorporeal membrane oxygenation for newborn respiratory failure Data from 715 cases. ASAIO Trans 34: 140–147, 1988. - PubMed
-
- Stolar CJ, Delosh T, Bartlett RH: Extracorporeal life support organization 1993. ASAIO J 39: 976–979, 1993. - PubMed
-
- UK Collaborative Randomised Trial of Neonatal Extracorporeal Membrane Oxygenation: UK Collaborative ECMO Trail Group. Lancet 348: 75–82, 1996. - PubMed
-
- Mugford M, Elbourne D, Field D: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants. Cochrane Database Syst Rev (3): CD001340, 2008. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources